Celltrion USA said that it has entered into an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the pharmacy benefits services business of the Cigna Group's Evernorth and one of the nation's leading health insurers, that will help expand patient access to ZYMFENTRA (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab.
The agreement, effective August 1, 2024, lists ZYMFENTRA as the preferred medication on the Cigna's medical formulary serving 16.1 million insured lives.
ZYMFENTRA was approved by the FDA in October 2023 for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) following treatment with an infliximab product administered intravenously.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.